Clinical characteristics of patients with pulmonary sarcoidosis treated with systemic steroids in Japan
Approximately one-third of patients received an initial steroid dose of PSL ≤ 10 mg/day for pulmonary sarcoidosis. This was mostly effective and the withdrawal rate was relatively high. Our results support that some Japanese patients with pulmonary sarcoidosis may successfully receive an initial dose of PSL ≤ 10 mg/day.
Authors
- Chiyoko Kono
- Michiru Sawahata (ORCID: https://orcid.org/0000-0001-9220-3419)
- Makoto Maemondo (ORCID: https://orcid.org/0000-0002-1950-1943)
- Tsutomu Tamada
- Satoshi Konno
- Takeshi Kawanobe
- Masashi Bando (ORCID: https://orcid.org/0000-0002-7244-0385)
- Tetsuo Yamaguchi (ORCID: https://orcid.org/0000-0002-9641-4894)
- Hirokazu Kimura (ORCID: https://orcid.org/0000-0002-9835-6659)
- Takafumi Suda (ORCID: https://orcid.org/0000-0001-5300-0504)
- Noriharu Shijubo
- Takeshi Hattori
Institutions
- Tokuyama (Japan) (JP)
- Jichi Medical University (JP)
- Tohoku University (JP)
- Hokkaido University (JP)
- Hamamatsu University School of Medicine (JP)
- National Hospital Organization Hokkaido Medical Center (JP)
- Hokkaido hospital (JP)
- JR Tokyo General Hospital (JP)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fmed.2025.1567334
- Primary Topic
- Sarcoidosis and Beryllium Toxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Ministry of Health, Labour and Welfare
- Japan Society for the Promotion of Science